ArticleJournal of Brown hospital medicine2026
Gemcitabine-Induced Pseudocellulitis in Metastatic Pancreatic Cancer.
Article in Journal of Brown hospital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gemcitabine-induced pseudocellulitis is a noninfectious inflammatory reaction that closely mimics bacterial cellulitis and can result in substantial diagnostic uncertainty and interruptions in cancer care. We report the case of a woman in her mid-seventies with metastatic pancreatic adenocarcinoma who developed recurrent bilateral lower extremity erythema and edema following gemcitabine therapy. The condition resulted in three unplanned hospitalizations, multiple chemotherapy delays, and five courses of broad-spectrum antibiotics, ultimately leading to antibiotic-associated Clostridioides difficile colitis. The diagnosis of gemcitabine-induced pseudocellulitis was established only during the third hospitalization after recognition of the bilateral symmetric distribution, normal inflammatory markers, negative microbiologic cultures, and a reproducible temporal relationship with gemcitabine administration. Gemcitabine was discontinued, supportive measures were initiated, and the patient's symptoms resolved completely. This case highlights the considerable oncologic and healthcare burden associated with delayed recognition of gemcitabine-induced pseudocellulitis and underscores the importance of early diagnosis by the hematology-oncology team to avoid unnecessary hospitalizations, inappropriate antibiotic exposure, and interruptions in cancer-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.